Aeglea shareholders approve increase in authorized shares to 400M and preferred conversion

Spyre Therapeutics, Inc.

Authorized common shares increased from 20M to 400M via Certificate of Amendment.
Stockholders approved issuance of up to 43.45M shares upon conversion of Series A Preferred Stock.
Amendment and restatement of 2016 Equity Incentive Plan approved.
Pro forma shares outstanding ~47.8M after full Series A conversion and pre-funded warrant exercise.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Spyre Therapeutics, Inc.: Increased authorized common stock shares from 20,000,000 to 400,000,000 (effective 2023-11-21).

Change: charter amendment
Effective: 2023-11-21

Exact text from the filing

On November 21, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) implemented an increase in the number of authorized shares of its common stock, par value $0.0001 per share (“Common Stock”), from 20,000,000 to 400,000,000 pursuant to a Certificate of Amendment to the Company’s Certificate of Incorporation, a copy of which is filed herewith as Exhibit 3.1.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Spyre Therapeutics, Inc. shareholders approved Amendment to the Certificate of Incorporation to increase authorized shares of Common Stock from 20,000,000 to 400,000,000 at the 2023-11-21 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-11-21

Exact text from the filing

Proposal No. 3 The Company’s stockholders adopted and approved an amendment to the Company’s Certificate of Incorporation, as amended and restated, to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000. For Against Abstain Broker Non-Votes 3,237,929 261,504 1,958 N/A

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Spyre Therapeutics, Inc. shareholders approved Approval of issuance of up to 43,453,560 shares of Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock at the 2023-11-21 meeting.

Outcome: passed
Meeting: 2023-11-21

Exact text from the filing

Proposal No. 1 The Company’s stockholders approved, for the purpose of complying with the applicable provisions of Nasdaq Listing Rule 5635(a), the issuance of up to 43,453,560 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”), issued in June 2023. For Against Abstain Broker Non-Votes 2,457,804 17,677 529 507,572

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Spyre Therapeutics, Inc. shareholders approved Adjournment or postponement of the Special Meeting to solicit additional votes for Proposals 1, 2 and/or 3 at the 2023-11-21 meeting.

Outcome: passed
Meeting: 2023-11-21

Exact text from the filing

Proposal No. 4 The Company’s stockholders adopted and approved an adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals 1, 2 and/or 3. For Against Abstain Broker Non-Votes 2,848,064 651,163 2,164 N/A

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Spyre Therapeutics, Inc. shareholders approved Amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan at the 2023-11-21 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-11-21

Exact text from the filing

Proposal No. 2 The Company’s stockholders approved the amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan. For Against Abstain Broker Non-Votes 2,244,907 748,367 545 507,572

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-282424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.